Biozone Pharmaceuticals, Cocrystal Discovery deal
On Jan. 3, Biozone said it completed its merger with Cocrystal. The combined company, which will initially continue to trade on the OTCBB, plans to apply for a name and ticker change in the coming months. The combined company will be named Cocrystal Pharma Inc. and headquartered in Bothell. The companies announced the stock deal in November. Biozone develops and manufactures OTC drugs on behalf of healthcare product marketing companies and national retailers. Cocrystal is developing antivirals against HCV, influenza, human rhinovirus, dengue and norovirus. Cocrystal's HCV program targets two replication enzymes, with its polymerase program at lead optimization and its helicase program at lead identification stage (see BioCentury, Dec. 9, 2013). ...